Applied Filters
SPCs and the unitary patent system: what now?
Brexit will have significant consequences for the UK regarding SPCs and the unitary patent system, while the UPC’s proposed start date of early 2017 looks highly unlikely, say Christopher Stothers and Paul Abbott of Arnold & Porter.
Biomedical patents: the quest for balance
The US Supreme Court’s Mayo and Myriad decisions have brought challenges to subject matter eligibility to the forefront in the biomedical industry, but they do not signal the end of biomedical patents. Pat Carson and Mira Atanassova Mulvaney of Kirkland & Ellis report.
Drug price regulation in Brazil: Roche faces IP rights abuse claims
The Brazilian Federal Prosecutor’s Office has taken court action against Roche for allegedly abusing IP rights in its sales of Herceptin to state governments. Anderson Ribeiro and Ricardo Campello of Provedel Advogados analyse the case.
Brexit and IP: business as usual, for now
Following the UK’s vote to leave the EU, it is business as usual for life sciences companies working with intellectual property, at least for now, says Claire Phipps-Jones of Bristows.
Freeing Africa from hunger
Africa Harvest is working towards reducing hunger and poverty in some of the world’s poorest countries. Dr Florence Wambugu, founder of the organisation, tells LSIPR more about its work.
Biotech in Birmingham: Alta Innovations’ story
Birmingham—Britain’s second city—with a leading university for research and development, allows biotech companies to enjoy the benefits of a cluster, as James Wilkie, CEO of Alta Innovations, the commercial spinout of the University of Birmingham, told LSIPR.
A sense of relief: enforcing second medical use patents
Owners of second medical use patents may need to think outside the box in terms of the relief they seek for infringement, says Katie Hutchinson of Bristows.
Europe v US: the patentability of diagnostic claims
Researchers should keep in mind that broad claims applying the discovery of a biomarker and disease correlation are currently patentable in Europe but not in the US. Andrew Carridge and Neil Thornton of Reddie & Grose report.
Patent portfolios: maximise the value and minimise the cost
Proactively managing patent portfolios is an investment that pays for itself in reduced patent costs. Bruno Reynolds, who works at the consultancy arm of Isis Innovation, the technology transfer company of the University of Oxford, explains more.
Partnering for profit
Despite its troubled start, Brazil’s Product Development Partnerships programme is now entering a new stage of its development with the introduction of a more complete system for regulation, but there’s also more scope for patent infringement, say Otto Licks and Ricardo Campello of Licks Attorneys.
